Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

STERISHEALTHCARE 573431969ec6680ff811d9bc Products https://www.sterisindia.com
{ "products": [ { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-10-02T11:20:20.402Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6891b0287b16001ae8bc9da2", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "CITICOTIME PM", "description": "CITICOTIME PM is a specialized formulation combining Citicoline 500mg and Piracetam 800mg in tablet form, designed to enhance brain health and cognitive functions. This combination harnesses the synergistic effects of two well-researched nootropic agents—citicoline and piracetam tablets—widely used in neurological therapies. Primarily, this medicine supports nerve cell nourishment, protects neurons from damage, and aids in improving memory, focus, and recovery in brain-related conditions such as stroke. Its unique formulation offers neuroprotection and cognitive enhancement, making it an important therapeutic option in treating stroke and other cognitive impairments.\n\nWhat is CITICOTIME PM?\nCITICOTIME PM contains a combination of two active ingredients: Citicoline 500mg, a neuroprotective compound that promotes brain cell repair and function, and Piracetam 800mg, which enhances neuronal communication and cognitive processes. Together, they work to support brain metabolism, improve blood flow, and strengthen cognitive resilience. This formulation is often prescribed to patients recovering from neurological injuries or those experiencing cognitive decline.\n\nUses of Citicoline and Piracetam Tablets\n\nTreatment and recovery support in stroke patients to restore brain function\n\nImprovement of memory, learning ability, and cognitive performance\n\nManagement of neurological disorders such as dementia and Alzheimer's disease\n\nNeuroprotection against brain cell damage caused by trauma or ischemia\n\nEnhancement of mental alertness and reduction of cognitive fatigue\n\nSupport in conditions involving cognitive impairment due to aging or injury\n\nCiticoline + Piracetam is used in the treatment of stroke. Citicoline + Piracetam is a combination of two medicines: Citicoline and Piracetam. Citicoline is a nerve protecting medicine. It works on the brain by nourishing the nerve cells, protects them from damage and improves their survival.\n\nCiticoline and Piracetam Tablets Dosage\nThe recommended dosage depends on the patient's condition, age, and response to therapy. Typically, CITICOTIME PM is taken once or twice daily as prescribed by a healthcare professional. Each tablet delivers Citicoline 500mg and Piracetam 800mg, providing an effective dose for neuroprotection and cognitive support. It should be swallowed whole with water, preferably after meals to reduce gastrointestinal discomfort. Dosage adjustments may be necessary in patients with kidney impairment or other comorbidities. It is critical to follow a doctor's prescribed dosage and not to self-medicate.\n\nSide Effects of Citicoline and Piracetam Tablets\nWhile generally well tolerated, some individuals may experience side effects, which are usually mild and temporary, including:\n\nHeadache\n\nNausea and stomach discomfort\n\nInsomnia or trouble sleeping\n\nNervousness or agitation\n\nDizziness and vertigo\n\nWeight gain in some cases\n\nRare allergic reactions such as skin rash or swelling\n\nChanges in blood pressure or heart rate (typically uncommon)\n\nIf severe side effects or allergic reactions occur, immediate medical attention is advised.\n\nPrecautions Before Using CITICOTIME PM\n\nConsult a doctor before use if you have a history of brain hemorrhage, bleeding disorders, or gastrointestinal ulcers.\n\nUse caution in elderly patients and those with renal or hepatic impairment.\n\nAvoid driving or operating heavy machinery until you know how the medicine affects you.\n\nDo not consume alcohol while taking this medication, as it may increase side effects like drowsiness or nervousness.\n\nInform your healthcare provider if you are pregnant, trying to conceive, or breastfeeding, as safety in these conditions is not fully established.\n\nDo not abruptly stop the medication without medical advice to avoid withdrawal symptoms such as muscle twitching.\n\nDrug Interactions: What Drugs Interact with CITICOTIME PM?\n\nAnticoagulants or blood thinners may increase the risk of bleeding.\n\nOther central nervous system (CNS) stimulants or depressants can enhance side effects like dizziness or drowsiness.\n\nMedications processed by kidneys require careful monitoring as both citicoline and piracetam are primarily excreted renally.\n\nAlcohol consumption can exacerbate side effects, especially sedation and nervousness.\n\nAlways inform your doctor about all medications and supplements you are taking to avoid harmful interactions.\n\nCITICOTIME PM, with citicoline 500mg and piracetam 800mg, is a reliable choice for managing stroke recovery and cognitive disorders by protecting and nourishing nerve cells, improving brain function, and supporting neuronal survival. Proper medical supervision is essential to maximize benefits and minimize risks associated with citicoline and piracetam tablets uses and dosage.", "price": 529.0, "discountamount": 159.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2155, "imageuri": "https://productimages.withfloats.com/actual/6891b02f5058847bfcd48899.png", "tileimageuri": "https://productimages.withfloats.com/tile/6891b02f5058847bfcd48899.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-05T07:18:00.92Z", "updatedon": "2025-08-05T07:18:00.92Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/citicotime-pm/2155", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "citicoline and piracetam tablets", "category": "NEUROLOGY RANGE", "tags": [ "citicoline and piracetam tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "681c5e9e5a26e4010ea42029", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ST-GLIPTIN M 100/ 1000", "description": "ST-GLIPTIN M 100/1000 is an advanced oral antidiabetic medication designed for the effective management of Type 2 Diabetes Mellitus. This powerful combination of Sitagliptin (100 mg) and Metformin Hydrochloride (1000 mg) offers dual action in controlling elevated blood glucose levels, especially in patients who do not respond adequately to metformin or sitagliptin alone. It is intended for adults and is generally used in conjunction with diet and exercise to enhance glycemic control.\n\nKey Ingredients\nSitagliptin (100 mg)\nSitagliptin is a DPP-4 (Dipeptidyl Peptidase-4) inhibitor that increases the levels of incretin hormones, which help regulate blood sugar by increasing insulin release and decreasing glucagon levels.\n\nMetformin Hydrochloride (1000 mg)\nMetformin belongs to the biguanide class of antidiabetics. It works by reducing the amount of sugar produced by the liver and improves the body’s sensitivity to insulin, facilitating better glucose utilization.\n\nKey Benefits\nHelps reduce both fasting and postprandial (after-meal) blood glucose levels effectively\nImproves overall glycemic control in patients with Type 2 diabetes\nCombines two different mechanisms of action for better diabetes management\nMinimizes the risk of hypoglycemia compared to other antidiabetic therapies\nMay support weight neutrality or slight weight loss in diabetic individuals\n\nHow Does It Work?\nST-GLIPTIN M 100/1000 works through a synergistic mechanism by combining two effective antidiabetic agents:\n\nSitagliptin enhances the levels of incretin hormones, which help the pancreas produce more insulin and reduce the secretion of glucagon, especially when blood sugar is high.\nMetformin reduces hepatic glucose production and increases insulin sensitivity, which helps the body use glucose more efficiently.\nTogether, these agents provide comprehensive blood sugar control by addressing multiple physiological pathways involved in glucose metabolism.\n\nDirections for Use\nTake ST-GLIPTIN M 100/1000 exactly as prescribed by your physician.\nIt is typically taken once or twice daily with meals to reduce gastrointestinal side effects and optimize absorption.\nSwallow the tablet whole with water. Do not crush or chew the tablet.\nMaintain a balanced diet and follow an active lifestyle for best results.\nRegular blood sugar monitoring is essential to assess effectiveness and make any necessary dosage adjustments.\n\nSide Effects\nCommon side effects may include nausea, diarrhea, stomach upset, or headache.\nSome individuals may experience respiratory tract infections, sore throat, or a runny nose.\nLactic acidosis is a rare but serious side effect associated with high-dose metformin—seek immediate medical attention if symptoms like unusual fatigue, muscle pain, difficulty breathing, or abdominal discomfort occur.\nAllergic reactions such as rash, itching, or swelling are uncommon but possible.\nAlways inform your doctor of any persistent or bothersome side effects for timely intervention.", "price": 225.0, "discountamount": 68.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "1001000 works", "100 1000stgliptin", "work stgliptin", "balanced diet", "tablet maintain", "diabetic individuals", "sitagliptin 100 mg", "timely intervention", "rash itching", "medical attention", "highdose metforminseek", "assess effectiveness", "active lifestyle", "pancreas produce", "synergistic mechanism", "antidiabetic therapies", "hypoglycemia compared", "glycemic control", "biguanide class", "incretin hormones", "respond adequately", "powerful combination", "insulin facilitating", "sugar produced", "side effect", "bodys sensitivity", "effective management", "blood sugar", "increases insulin sensitivity", "regulate blood sugar", "glucose metabolism directions", "increasing insulin release", "bothersome side effects", "diabetes management minimizes", "optimize absorption swallow", "slight weight loss", "support weight neutrality" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2107, "imageuri": "https://productimages.withfloats.com/actual/681c5e9f5e6dd8f19a0309c3.png", "tileimageuri": "https://productimages.withfloats.com/tile/681c5e9f5e6dd8f19a0309c3.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-08T07:34:54.516Z", "updatedon": "2025-05-08T07:35:36.782Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/st-gliptin-m-100-1000/2107", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "sitagliptin and metformin hydrochloride tablets", "category": "DIABETIC RANGE", "tags": [ "Sitagliptin and Metformin hydrochloride tablets Uses in Hindi", "sitagliptin and metformin hydrochloride tablets 50/1000 uses in hindi", "sitagliptin and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e7ff07e47881008f6860e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIMETAZ CR 80 ", "description": "TRIMETAZ CR 80 \nTrimetazidine (80mg)\nIntroduction\nTRIMETAZ CR 80 is a medication containing Trimetazidine hydrochloride, formulated to treat angina pectoris and certain other cardiovascular conditions. It is known for its metabolic effects on the heart muscle, improving myocardial efficiency and reducing symptoms associated with ischemic heart disease.\n\nComposition\n\nTrimetazidine (80mg): The active ingredient, Trimetazidine, acts as a cellular metabolic agent that enhances myocardial glucose utilization and improves energy production in the heart muscle.\nMechanism of Action\nTrimetazidine exerts its therapeutic effects through several mechanisms:\n\nMetabolic Regulation: Shifts myocardial energy substrate utilization from fatty acids toward glucose oxidation, which is more efficient and requires less oxygen.\nAnti-ischemic Effect: Protects the heart against ischemic damage by preserving cellular energy metabolism and reducing oxidative stress.\nImprovement in Symptomatology: Reduces angina symptoms such as chest pain, shortness of breath, and exercise intolerance by enhancing myocardial function.\nIndications\nTRIMETAZ CR 80 is indicated for:\n\nChronic Stable Angina Pectoris: Used as adjunctive therapy in patients who are inadequately controlled with other anti-anginal medications.\nIschemic Heart Disease: Helps improve myocardial function and reduce symptoms associated with coronary artery disease.\nDosage and Administration\n\nThe usual dosage of TRIMETAZ CR 80 is one tablet (80mg) taken orally twice daily, preferably with meals.\nThe extended-release formulation ensures sustained therapeutic levels of Trimetazidine throughout the day.\nDosage adjustments may be necessary based on individual patient response and tolerance.\nSide Effects\nCommon side effects may include:\n\nHeadache\nDizziness\nNausea\nGastrointestinal disturbances (such as abdominal pain or diarrhea)\nSevere side effects are rare but may include:\n\nAllergic reactions (rash, itching, swelling)\nExtrapyramidal symptoms (involuntary movements)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with severe renal impairment or hepatic dysfunction, as Trimetazidine metabolism may be altered.\nMonitor patients for signs of extrapyramidal symptoms, especially in patients with Parkinson's disease or other movement disorders.\nAvoid abrupt discontinuation of Trimetazidine, as it may worsen angina symptoms.\nDrug Interactions\n\nTrimetazidine may interact with other medications that affect myocardial metabolism or cardiac function, including beta-blockers and calcium channel blockers. Close monitoring is recommended when used concomitantly.\nConclusion\nTRIMETAZ CR 80 is a valuable therapeutic option for managing chronic stable angina pectoris and ischemic heart disease by improving myocardial efficiency and reducing symptoms associated with cardiac ischemia. Its mechanism of action, focusing on metabolic modulation and anti-ischemic effects, makes it an effective adjunctive therapy in patients with inadequate symptom control on standard anti-anginal medications. Proper dosage, administration, and monitoring for side effects are essential to ensure safe and effective use of TRIMETAZ CR 80 in cardiovascular patients. Consultation with a healthcare provider is recommended for personalized treatment plans and management of cardiac conditions with TRIMETAZ CR 80.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 435.0, "discountamount": 130.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "one tablet", "chest pain", "less oxygen", "fatty acids", "TRIMETAZ CR", "usual dosage", "heart muscle", "Proper dosage", "effective use", "abdominal pain", "angina symptoms", "ischemic damage", "Close monitoring", "cardiac ischemia", "oxidative stress", "cardiac function", "Drug Interactions", "active ingredient", "glucose oxidation", "metabolic effects", "energy production", "other medications", "Dosage adjustments", "Allergic reactions", "adjunctive therapy", "several mechanisms", "cardiac conditions", "healthcare provider", "Hepatic dysfunction", "myocardial function", "therapeutic effects", "Severe side effects", "Common side effects", "metabolic modulation", "Metabolic Regulation", "liver function tests", "involuntary movements", "anti-ischemic effects", "myocardial efficiency", "myocardial metabolism", "abrupt discontinuation", "ischemic heart disease", "Extrapyramidal symptoms", "cardiovascular patients", "coronary artery disease", "severe renal impairment", "Trimetazidine metabolism", "cellular metabolic agent", "other movement disorders", "calcium channel blockers", "cellular energy metabolism", "inadequate symptom control", "Trimetazidine hydrochloride", "valuable therapeutic option", "individual patient response", "extended-release formulation", "sustained therapeutic levels", "personalized treatment plans", "Gastrointestinal disturbances", "other anti-anginal medications", "myocardial glucose utilization", "Chronic Stable Angina Pectoris", "other cardiovascular conditions", "standard anti-anginal medications", "myocardial energy substrate utilization" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1938, "imageuri": "https://productimages.withfloats.com/actual/668e7ff3f07c99c3af8e8504.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e7ff3f07c99c3af8e8504.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:34:56.538Z", "updatedon": "2024-07-10T12:34:56.538Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trimetaz-cr-80-/1938", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIMETAZ CR 80 ", "category": "CARDIOLOGYRANGE", "tags": [ "Trimetazidine 80mg price", "Trimetazidine 35 mg uses", "Trimetazidine 80 mg brand name", "When to stop taking trimetazidine", "Trimetazidine hydrochloride extended release CAPSU", "Trimetazidine mechanism of action", "Trimetazidine 35 mg brand name", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662c81c7247ae19c482b3d9", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE 100 ", "description": "VILDIABATE 100 \nVildagliptin (100mg)\nIntroduction to VILDIABATE 100\nVILDIABATE 100 is an oral medication designed for the management of type 2 diabetes mellitus. It contains Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Vildagliptin helps regulate blood sugar levels by enhancing the body’s natural ability to produce insulin and control glucose production. This medication is used in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Component and Mechanism of Action\nVildagliptin 100mg\nVildagliptin is a potent and selective DPP-4 inhibitor. It works by inhibiting the DPP-4 enzyme, which is responsible for breaking down incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These incretin hormones play a crucial role in glucose metabolism:\n\nGLP-1: Stimulates insulin secretion from the pancreatic beta cells in a glucose-dependent manner, inhibits glucagon release, slows gastric emptying, and reduces appetite.\nGIP: Enhances insulin secretion post-meal, aiding in the regulation of blood glucose levels.\nBy increasing the levels of these incretin hormones, Vildagliptin helps to improve insulin secretion in response to meals and reduces the amount of glucose produced by the liver.\n\nBenefits of VILDIABATE 100\nEffective Blood Sugar Control\nPostprandial Glucose Control: VILDIABATE 100 helps manage postprandial (after-meal) blood sugar levels by enhancing the body's natural response to food intake.\nFasting Glucose Control: By reducing hepatic glucose production, it also helps lower fasting blood sugar levels.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: Vildagliptin is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nHow to Use VILDIABATE 100\nDosage and Administration\nRecommended Dosage: The typical dosage of VILDIABATE 100 is one tablet taken once or twice daily, depending on individual needs and the healthcare provider's instructions.\nAdministration: Take the tablet with or without food. Swallow it whole with a glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE 100 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is important to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-100-133452", "price": 275.0, "discountamount": 82.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "body", "EMAIL", "Order", "meals", "water", "glass", "GLP-1", "liver", "adults", "Action", "amount", "option", "potent", "readings", "Low Risk", "appetite", "exercise", "patients", "same time", "Mechanism", "regulation", "VILDIABATE", "one tablet", "Guidelines", "management", "food intake", "weight gain", "Optimal Use", "information", "conjunction", "Adjustments", "Introduction", "Vildagliptin", "sterisonline", "best results", "crucial role", "DPP-4 enzyme", "Hypoglycemia", "instructions", "sterispharma", "Key Component", "CALL/WHATSAPP", "typical dosage", "Consistent Use", "Administration", "treatment plan", "Weight Neutral", "natural ability", "oral medication", "low blood sugar", "glucagon release", "DPP-4) inhibitor", "natural response", "glycemic control", "individual needs", "gastric emptying", "insulin secretion", "incretin hormones", "glucose metabolism", "Recommended Dosage", "Regular monitoring", "healthcare provider", "blood glucose levels", "pancreatic beta cells", "dipeptidyl peptidase-4", "Fasting Glucose Control", "meal) blood sugar levels", "type 2 diabetes mellitus", "glucose-dependent manner", "selective DPP-4 inhibitor", "Additional Health Benefits", "hepatic glucose production", "other diabetes medications", "Postprandial Glucose Control", "Effective Blood Sugar Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1514, "imageuri": "https://productimages.withfloats.com/actual/667d3bc9c134db5b38ba8354.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3bc9c134db5b38ba8354.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:43:08.09Z", "updatedon": "2024-06-27T10:15:31.785Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vildiabate-100-/1514", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE 100 ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin 100 mg uses", "", "vildagliptin 100 mg generic medicine", "vildagliptin 100 mg side effects", "", "vildagliptin sustained release tablets 100 mg", "vildagliptin 100 mg brands in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662acf3161afa2274ff5e9d", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE 50 ", "description": "VILDIABATE 50 \nVildagliptin (50mg)\nIntroduction to VILDIABATE 50\nVILDIABATE 50 is an oral medication specifically designed for the management of type 2 diabetes mellitus. It contains Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Vildagliptin works by enhancing the body's natural ability to regulate blood sugar levels, especially after meals. This medication is used in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nMechanism of Action\nVildagliptin\nVildagliptin is a potent and selective DPP-4 inhibitor. It works by inhibiting the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones play a crucial role in glucose metabolism:\n\nGLP-1: Stimulates insulin secretion from the pancreatic beta cells in a glucose-dependent manner, inhibits glucagon release, slows gastric emptying, and reduces appetite.\nGIP: Enhances insulin secretion post-meal, aiding in the regulation of blood glucose levels.\nBy increasing the levels of these incretin hormones, Vildagliptin helps to improve insulin release in response to meals and reduces the amount of glucose produced by the liver.\n\nBenefits of VILDIABATE 50\nEffective Blood Sugar Control\nPostprandial Glucose Control: VILDIABATE 50 helps manage postprandial (after-meal) blood sugar levels by enhancing the body's natural response to food intake.\nFasting Glucose Control: By reducing hepatic glucose production, it also helps lower fasting blood sugar levels.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: Vildagliptin is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nHow to Use VILDIABATE 50\nDosage and Administration\nRecommended Dosage: The typical dosage of VILDIABATE 50 is one tablet taken once or twice daily, depending on individual needs and the healthcare provider's instructions.\nAdministration: Take the tablet with or without food. Swallow it whole with a glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE 50 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is important to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-50-133451", "price": 249.0, "discountamount": 74.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "body", "diet", "liver", "Order", "glass", "meals", "water", "EMAIL", "GLP-1", "option", "potent", "adults", "amount", "readings", "Low Risk", "appetite", "patients", "exercise", "Mechanism", "same time", "one tablet", "regulation", "VILDIABATE", "Guidelines", "management", "Adjustments", "weight gain", "information", "Optimal Use", "food intake", "conjunction", "Introduction", "sterisonline", "crucial role", "DPP-4 enzyme", "Hypoglycemia", "instructions", "sterispharma", "best results", "CALL/WHATSAPP", "treatment plan", "Consistent Use", "Weight Neutral", "typical dosage", "Administration", "natural ability", "oral medication", "low blood sugar", "insulin release", "glucagon release", "natural response", "DPP-4) inhibitor", "gastric emptying", "individual needs", "glycemic control", "incretin hormones", "insulin secretion", "Regular monitoring", "glucose metabolism", "Recommended Dosage", "Action Vildagliptin", "healthcare provider", "blood glucose levels", "pancreatic beta cells", "dipeptidyl peptidase-4", "Fasting Glucose Control", "meal) blood sugar levels", "type 2 diabetes mellitus", "glucose-dependent manner", "selective DPP-4 inhibitor", "other diabetes medications", "hepatic glucose production", "Additional Health Benefits", "Postprandial Glucose Control", "Effective Blood Sugar Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1494, "imageuri": "https://productimages.withfloats.com/actual/6662acf5364f23242470bc7d.png", "tileimageuri": "https://productimages.withfloats.com/tile/6662acf5364f23242470bc7d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T06:47:15.345Z", "updatedon": "2024-06-28T11:41:29.762Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-50-/1494", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE 50 ", "category": "DIABETIC RANGE", "tags": [ "VILDIABATE 50", "Vildagliptin (50mg)", "Vildagliptin 50mg side effects", "Vildagliptin tablets 50 mg uses", "Vildagliptin 50 mg price", "Vildagliptin 50 mg and metformin 500 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661a9f67247ae19c482a99a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD M 1000 ", "description": "TENELIGOLD M 1000 \nMetformin SR (1000mg), Teneligliptin (20mg)\nIntroduction to TENELIGOLD M 1000\nTENELIGOLD M 1000 is a combination medication that includes Metformin Hydrochloride Sustained Release (SR) 1000mg and Teneligliptin 20mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Metformin and Teneligliptin, TENELIGOLD M 1000 offers comprehensive glycemic control, helping patients effectively manage their blood sugar levels.\n\nWhat are Metformin and Teneligliptin?\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release formulation ensures a prolonged effect throughout the day.\n\nOverview of Teneligliptin\nTeneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that helps control blood sugar levels by enhancing the body's ability to regulate insulin after meals. It works by inhibiting the DPP-4 enzyme, which results in prolonged activity of incretin hormones that play a significant role in glucose metabolism.\n\nBenefits of TENELIGOLD M 1000\nEffective Blood Sugar Management\nDual Mechanism of Action: Metformin improves insulin sensitivity and reduces hepatic glucose production, while Teneligliptin enhances insulin release and reduces glucagon levels after meals, providing comprehensive glycemic control.\nPostprandial and Fasting Glucose Control: This combination helps manage both postprandial (after-meal) and fasting blood sugar levels, offering all-around glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: TENELIGOLD M 1000 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, this medication can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nLow Risk of Hypoglycemia: When used alone or in combination with Metformin, Teneligliptin has a low risk of causing hypoglycemia compared to some other diabetes medications.\nHow to Use TENELIGOLD M 1000\nDosage and Administration\nRecommended Dosage: The typical dosage of TENELIGOLD M 1000 is one tablet taken once or twice daily, depending on your healthcare provider's instructions. The dosage may be adjusted based on individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take TENELIGOLD M 1000 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/teneligold-m-1000-133448", "price": 144.0, "discountamount": 43.2, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "body", "Diet", "Order", "EMAIL", "liver", "water", "meals", "Action", "amount", "option", "ability", "Support", "Overview", "Low Risk", "readings", "biguanide", "one tablet", "full glass", "overweight", "neuropathy", "Guidelines", "information", "retinopathy", "utilization", "Adjustments", "Optimal Use", "instructions", "Hypoglycemia", "Introduction", "Metformin SR", "Postprandial", "sterispharma", "Reduced Risk", "TENELIGOLD M", "best results", "sterisonline", "DPP-4 enzyme", "Teneligliptin", "effectiveness", "CALL/WHATSAPP", "typical dosage", "treatment plan", "Administration", "Consistent Use", "Dual Mechanism", "obese patients", "glucagon levels", "insulin release", "DPP-4) inhibitor", "Exercise Adjunct", "prolonged effect", "significant role", "weight neutrality", "excellent adjunct", "Weight Management", "incretin hormones", "prolonged activity", "glucose metabolism", "Recommended Dosage", "modest weight loss", "Diabetes Management", "blood sugar control", "insulin sensitivity", "healthcare provider", "individual response", "dipeptidyl peptidase-4", "combination medication", "cardiovascular disease", "lifestyle modifications", "long-term complications", "Fasting Glucose Control", "type 2 diabetes mellitus", "complementary mechanisms", "peripheral glucose uptake", "stable blood sugar levels", "other diabetes medications", "Additional Health Benefits", "hepatic glucose production", "gastrointestinal discomfort", "sustained-release formulation", "comprehensive glycemic control", "Effective Blood Sugar Management", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1476, "imageuri": "https://productimages.withfloats.com/actual/6661aa01a771049a81dc9ef8.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661aa01a771049a81dc9ef8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:22:14.966Z", "updatedon": "2024-06-28T12:38:50.531Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-m-1000-/1476", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD M 1000 ", "category": "DIABETIC RANGE", "tags": [ "TENELIGOLD M 1000", "Metformin SR (1000mg)", "Teneligliptin (20mg)", "Metformin SR 1000 mg uses", "Metformin SR 1000 mg side effects", "Metformin SR 1000 Mg Uses in Hindi", "Metformin SR 1000 price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }

Still searching for
hepatic metabolism?

Still searching for
hepatic metabolism?

Chat with us